Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS 3rd.

J Clin Invest. 2013 Aug;123(8):3231-42. doi: 10.1172/JCI67655. Epub 2013 Jul 8.

2.

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS.

J Clin Invest. 2014 Nov;124(11):4737-52. doi: 10.1172/JCI76375. Epub 2014 Sep 24.

4.

Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.

Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK.

J Immunol. 2007 May 1;178(9):5635-42.

5.

MerTK is required for apoptotic cell-induced T cell tolerance.

Wallet MA, Sen P, Flores RR, Wang Y, Yi Z, Huang Y, Mathews CE, Earp HS, Matsushima G, Wang B, Tisch R.

J Exp Med. 2008 Jan 21;205(1):219-32. doi: 10.1084/jem.20062293. Epub 2008 Jan 14.

6.

Increased hematopoietic cells in the mertk-/- mouse peritoneal cavity: a result of augmented migration.

Williams JC, Wagner NJ, Earp HS, Vilen BJ, Matsushima GK.

J Immunol. 2010 Jun 15;184(12):6637-48. doi: 10.4049/jimmunol.0902784. Epub 2010 May 14.

7.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.

8.

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.

Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P.

Blood. 2010 Mar 18;115(11):2264-73. doi: 10.1182/blood-2009-06-228684. Epub 2009 Nov 20.

9.
10.

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.

Png KJ, Halberg N, Yoshida M, Tavazoie SF.

Nature. 2011 Dec 14;481(7380):190-4. doi: 10.1038/nature10661.

PMID:
22170610
11.

P-selectin enhances growth and metastasis of mouse mammary tumors by promoting regulatory T cell infiltration into the tumors.

Nasti TH, Bullard DC, Yusuf N.

Life Sci. 2015 Jun 15;131:11-8. doi: 10.1016/j.lfs.2015.02.025. Epub 2015 Apr 10.

PMID:
25865803
12.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

13.

IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

Mattei F, Schiavoni G, Sestili P, Spadaro F, Fragale A, Sistigu A, Lucarini V, Spada M, Sanchez M, Scala S, Battistini A, Belardelli F, Gabriele L.

Neoplasia. 2012 Dec;14(12):1223-35.

14.

B7-1 and interleukin 12 synergistically induce effective antitumor immunity.

Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.

Cancer Res. 1995 Nov 1;55(21):4980-7.

15.

Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.

Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM.

Breast Cancer Res. 2013;15(5):R75.

16.

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.

Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.

Biol Blood Marrow Transplant. 2004 Aug;10(8):524-33.

17.

CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Müller CE, Murakami T, Robson SC.

Gastroenterology. 2010 Sep;139(3):1030-40. doi: 10.1053/j.gastro.2010.05.007. Epub 2010 Jun 25.

18.

Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM.

J Immunol. 2005 Jul 15;175(2):813-9.

19.

Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.

Nguyen KQ, Tsou WI, Calarese DA, Kimani SG, Singh S, Hsieh S, Liu Y, Lu B, Wu Y, Garforth SJ, Almo SC, Kotenko SV, Birge RB.

J Biol Chem. 2014 Sep 12;289(37):25737-49. doi: 10.1074/jbc.M114.570838. Epub 2014 Jul 29.

20.

A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.

Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR, Wang XY.

Cancer Res. 2013 Apr 1;73(7):2093-103. doi: 10.1158/0008-5472.CAN-12-1740. Epub 2013 Jan 18.

Items per page

Supplemental Content

Write to the Help Desk